2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö : 2024-06-08 |
|
2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö : 2024-06-08 ±³À°ÁÖÁ¦ : 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ ´ã´çÀÚ : ±èÇýÁø À̸ÞÀÏ : hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú Âü¼®¿¹»óÀÎ : 60¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 50,000¿ø ºñ°í ºñȸ¿ø 50,000¿ø
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 14:00~14:20 Standard risk ALL(acute lymphoblastic leukemia) ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë ) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 14:20~14:50 Very high risk ALL(acute lymphoblastic leukemia) ±èº¸°æ(¼¿ïÀÇ´ë ) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 14:50~15:10 Relapsed ALL(acute lymphoblastic leukemia) ±èÇý¸®(¿ï»êÀÇ´ë) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 15:10~15:25 °í¿ë·® methotrexate µ¶¼º ¿¹¹æÀ» À§ÇÑ glucarpidase Àӻ󿬱¸ ÃÖÁ¤À±(¼¿ïÀÇ´ë) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 15:25~15:40 ¼Ò¾Æ ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ Ä¡·áÀÇ ÁËÀûȸ¦ À§ÇÑ Ç×¾ÏÁ¦ Therapeutic Drug Monitoring Àӻ󿬱¸°³¹ß ±èÇý¸®(¿ï»êÀÇ´ë) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 15:40~15:55 ¼Ò¾Æ ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¸é¿ªÄ¡·á ¿¬°ü µ¶¼º Ä¡·áÁ¦ anakinraÀÇ È¿¿ë¼º Æò°¡ À¯Àç¿ø(°¡Å縯ÀÇ´ë ) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 16:30~17:00 The genomic landscape in pediatric ALL(acute lymphoblastic leukemia) ¹éÈñÁ¶(Àü³²ÀÇ´ë ) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 17:00~17:30 Current state of precision medicine in pediatric ALL(acute lymphoblastic leukemia) ½É¿¹Áö(°è¸íÀÇ´ë ) ±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 17:30~18:00 What¡¯s new in immunotherapy in pediatric ALL(acute lymphoblastic leukemia) ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë )
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|